339530-91-5

Usage

Uses

Used in Pharmaceutical Industry:
Fenbufen is utilized as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis. It is particularly effective in managing the associated pain and inflammation due to its ability to curb prostaglandin production.
Used in Pain Management:
Fenbufen serves as a pain reliever, addressing acute and chronic pain conditions by reducing the levels of prostaglandins that are typically elevated in response to injury or disease.
Used in Inflammation Reduction:
In conditions characterized by inflammation, fenbufen is applied to diminish the inflammatory response, providing relief from swelling and associated discomfort.

InChI:InChI=1/C10H11FO3S/c1-10(14,9(12)13)6-15-8-4-2-7(11)3-5-8/h2-5,14H,6H2,1H3,(H,12,13)

Upstream product

• 1098651-01-4 methyl 3-((4-fluorophenyl)thio)-2-hydroxy-2-methylpropanoate 
• 58653-97-7 methyl 2-methyl-2-oxiranecarboxylate 
• 371-42-6 4-Fluorothiophenol 

Downstream Products

• 873014-27-8 2-acetoxy-2-methyl-3-(4-fluorophenylthio) propionic acid 
• 1098651-02-5 C₁₀H₁₀ClFO₂S 
• 1463530-10-0 N-(4-cyano-3-(perfluoroethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide 
• 1365025-71-3 C₁₈H₁₃F₄N₃O₆S 
• 1365025-63-3 C₁₇H₁₃ClF₂N₂O₄S 
• 1365025-55-3 C₁₇H₁₄ClFN₂O₄S 
• 1365025-48-4 C₁₇H₁₅FN₂O₄S 
• 1365025-40-6 C₁₈H₁₃F₄N₃O₄S 
• 1365025-32-6 C₁₇H₁₃ClF₂N₂O₂S 
• 1365025-24-6 C₁₇H₁₄ClFN₂O₂S 
• 1365025-17-7 C₁₇H₁₅FN₂O₂S 
• 90356-78-8 N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide 

Relevant academic research and scientific papers

1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents

Sulfide and sulfonyl derivatives of 1,2,4-oxadiazoles were synthesized and screened by MTT assay on the prostate cancer cells, DU-145. Six compounds were identified as potential anti-prostate cancer agents with IC50 values ranging from 0.5 to 5

Improved procedure for the synthesis of bicalutamide

The object of the invention is an improved procedure for the synthesis of bicalutamide, characterised in that the 2-hydroxy-2-methyl-3-(4-fluorophenylthio) propionic acid initially produced undergoes a step to acylate the hydroxyl group in position 2 to give an intermediate 2-acyloxy-2-methyl-3-(4-fluorophenylthio) propionic acid, which allows the formation of a successive N-[4-cyano-3-(trifluoromethyl)-phenyl-]-3-[4-fluorophenylthio]-2-acyloxy-2-methyl-propionamide intermediate.

Procedure for the synthesis of bicalutamide

The object of the invention is an improved procedure for the synthesis of bicalutamide, characterised in that the 2-hydroxy-2-methyl-3-(4-fluorophenylthio) propionic acid initially produced undergoes a step to acylate the hydroxyl group in position 2 to give an intermediate 2-acyloxy-2-methyl-3-(4-fluorophenylthio) propionic acid, which allows the formation of a successive N-[4-cyano-3-(trifluoromethyl)-phenyl-]-3-[4-fluorophenylthio]-2-acyloxy-2-methyl-propionamide intermediate.

Methods of asymmetrically synthesizing enantiomers of Casodex, its derivatives and intermediates thereof

Methods of synthesizing pure enantiomers of acylanalides such as Casodex? (bicalutamide) and its derivatives utilizing a compound having a ring structure that, when opened, provides a substituent having the structure of Formula I: wherein R1is alkyl or haloalkyl having up to 4 carbons; R2is alkyl having up to 6 carbon atoms; and R3is CH2OR4where R4is hydrogen or benzyl, C(O)CH3, or C(O)OR5where R5is hydrogen or alkyl; are disclosed. Methods of synthesizing acylanalides such as Casodex? (bicalutamide) and/or derivatives thereof from a starting material of citramalic acid are also provided.

Novel process for preparing rac-bicalutamide and its intermediates

The present invention relates to a new process for the synthesis of racemic and optically active bicalutamide starting from ethyl pyruvate and methyl methacrylate. The present invention discloses processes of preparing bicalutamide intermediates including